• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Compugen Ltd. (Amendment)

    2/3/23 6:10:06 AM ET
    $CGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CGEN alert in real time by email
    SC 13G/A 1 cgen125235sc13ga4.htm AMENDMENT NO. 4
     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION  

    Washington, D.C. 20549 

     ________________ 

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 4)*

     

    Compugen, Ltd.
    (Name of Issuer)
     
    Ordinary Shares, par value NIS 0.01
    (Title of Class of Securities)
     
    M25722105
    (CUSIP Number)
     
    December 31, 2022
    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x       Rule 13d-1(b)

     

    o       Rule 13d-1(c)

     

    o       Rule 13d-1(d)

     

                                                                     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     Page 1 of 9 
     

     

    CUSIP No. M25722105  13G/A  

     

    1.

    NAMES OF REPORTING PERSONS

     

    Sumitomo Mitsui Trust Holdings, Inc.  (“SMTH”)

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) o
       

    (b) o

     

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Japan

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    0

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    0

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.00%

    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    HC, FI

      

     Page 2 of 9 
     

     

    CUSIP No. M25722105 13G/A  

     

    1.

    NAMES OF REPORTING PERSONS

     

    Nikko Asset Management Co., Ltd. (“NAM”)

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) o
       

    (b) o

     

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Japan

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    0

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    0

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.00%

    12.

    TYPE OF REPORTING PERSON

     

    IA, HC, FI

     

     Page 3 of 9 
     

      

    Item 1(a).Name of Issuer:

      

    Compugen, Ltd. 

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    Azrieli Center, 26 Harokmim St. Bldg D

     

    Holon L3 5885849, Israel

     

    Item 2(a).Name of Person Filing:

     

    Sumitomo Mitsui Trust Holdings, Inc.

     

    Nikko Asset Management Co., Ltd.

     

    Item 2(b).Address of Principal Business Office or, if None, Residence:

     

    SMTH: 1-4-1 Marunouchi, Chiyoda-ku, Tokyo 100-8233, Japan

     

    NAM: Midtown Tower, 9-7-1 Akasaka, Minato-ku, Tokyo 107-6242, Japan

     

    Item 2(c).Citizenship:

     

    SMTH: Japan

     

    NAM: Japan

     

    Item 2(d).Title of Class of Securities:

     

    Ordinary Shares, par value NIS 0.01

     

    Item 2(e).CUSIP Number:

     

    M25722105

     

     Page 4 of 9 
     

       

    Item 3.If this Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

     

    SMTH:

     

    (a) o  Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
         
    (b) o  Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
         
    (c) o  Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
         
    (d) o  Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
         
    (e) o  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
         
    (f) o  An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
         
    (g) x  A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
         
    (h) o  A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
    (i) o  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
         
    (j) x  A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
         
    (k) o  Group, in accordance with §240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: Parent Holding Company

     

    NAM:

     

    (a) o  Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
         
    (b) o  Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
         
    (c) o  Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
         
    (d) o  Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
         
    (e) x  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
         
    (f) o  An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
         
    (g) x  A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
         
    (h) o  A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
    (i) o  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
         
    (j) x  A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
         
    (k) o  Group, in accordance with §240.13d-1(b)(1)(ii)(K).

     

     Page 5 of 9 
     

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: Investment Adviser, Parent Holding Company

     

    Item 4.Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of issuer identified in Item 1.

     

    SMTH:    
      (a)   Amount beneficially owned: 0
      (b)   Percent of class: 0.00%
      (c)   Number of shares as to which such person has:
      (i)   Sole power to vote or to direct the vote: 0
      (ii)   Shared power to vote or to direct the vote: 0
      (iii)   Sole power to dispose or to direct the disposition of: 0
      (iv)  

    Shared power to dispose or to direct the disposition of: 0

     

    NAM:    
      (a)   Amount beneficially owned: 0
      (b)   Percent of class: 0.00%
      (c)   Number of shares as to which such person has:
      (i)   Sole power to vote or to direct the vote: 0
      (ii)   Shared power to vote or to direct the vote: 0
      (iii)   Sole power to dispose or to direct the disposition of: 0
      (iv)   Shared power to dispose or to direct the disposition of: 0

     

     

     Page 6 of 9 
     

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. x

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    See Exhibit A.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    See Exhibit A.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     Page 7 of 9 
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 3, 2023

     

      Sumitomo Mitsui Trust Holdings, Inc.
      (Company)
       
      /s/ Hideaki Takamiya
     

    (Signature)

     

    Hideaki Takamiya / Senior Manager of Risk Management Dept  

      (Name/Title)
       
      Nikko Asset Management Co.,Ltd 
      (Company)
       
      /s/ Atsushi Ohya
     

    (Signature)

     

    Atsushi Ohya / Head of Business Regulatory Compliance 

      (Name/Title)
       
     Page 8 of 9 
     

     

    Exhibit A

     

    Pursuant to the instructions in Item 6 and Item 7 of Schedule 13G, the securities being reported on by each of SMTH and NAM, as parent holding companies, are owned, or may be deemed to be beneficially owned, by their subsidiary Nikko Asset Management Americas, Inc., which is classified as an investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

     

     

    Page 9 of 9

     

     

     

    Get the next $CGEN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CGEN

    DatePrice TargetRatingAnalyst
    1/13/2025$4.00Outperform
    Oppenheimer
    8/5/2022$2.00Buy → Hold
    Jefferies
    2/25/2022$17.00 → $14.00Outperform
    Oppenheimer
    2/25/2022$16.00 → $9.00Outperform
    SVB Leerink
    More analyst ratings

    $CGEN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Compugen Reports Second Quarter 2025 Results

    First patient dosed in MAIA-ovarian platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer in July 2025Pooled analysis from three previously reported Phase 1 trials of COM701 in platinum resistant ovarian cancer to be presented at ESMO 2025Recruitment ongoing in Phase 1 trial of GS-0321 (COM503) a potential first-in-class anti-IL18BP antibody licensed to GileadPartner AstraZeneca plans to share updated rilvegostomig data from Phase 2 ARTEMIDE-01 in NSCLC and first data from Phase 2 TROPION-PanTumor03 in bladder cancer at ESMO 2025Solid financial position with cash runway expected to fund operations into 2027HOLON, Israel, Aug. 6, 2025 /PRNewswire/ -- 

    8/6/25 7:00:00 AM ET
    $CGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resistant Ovarian Cancer at ESMO 2025

    HOLON, Israel, July 28, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery powered by AI/ML, today announced that it will present a pooled analysis of data from three Phase 1 trials evaluating COM701 as monotherapy and combination therapy in heavily pretreated platinum resistant ovarian cancer patients at ESMO 2025, being held on October 17-21, 2025, in Berlin, Germany. Poster details: Title: COM701 in Ovarian Cancer: A Pooled Analysis of 3 Phase 1 Clinical Trials Speaker: Dr. Oladapo Yeku, Massachusetts General Hospital, Boston, MA, U.S.Poster presentation number: 1196PD

    7/28/25 7:00:00 AM ET
    $CGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Compugen to Release Second Quarter 2025 Results on Wednesday, August 6, 2025

    HOLON, Israel, July 23, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery powered by AI/ML, today announced that the Company will release its second quarter 2025 financial results on Wednesday, August 6, 2025, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET. To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, which i

    7/23/25 7:00:00 AM ET
    $CGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $CGEN
    SEC Filings

    View All

    Oppenheimer initiated coverage on Compugen with a new price target

    Oppenheimer initiated coverage of Compugen with a rating of Outperform and set a new price target of $4.00

    1/13/25 8:13:52 AM ET
    $CGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Compugen downgraded by Jefferies with a new price target

    Jefferies downgraded Compugen from Buy to Hold and set a new price target of $2.00

    8/5/22 7:15:52 AM ET
    $CGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Oppenheimer reiterated coverage on Compugen with a new price target

    Oppenheimer reiterated coverage of Compugen with a rating of Outperform and set a new price target of $14.00 from $17.00 previously

    2/25/22 8:45:50 AM ET
    $CGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Compugen Ltd.

    6-K - COMPUGEN LTD (0001119774) (Filer)

    8/6/25 7:33:58 AM ET
    $CGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Compugen Ltd.

    6-K - COMPUGEN LTD (0001119774) (Filer)

    8/6/25 7:01:16 AM ET
    $CGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Compugen Ltd.

    6-K - COMPUGEN LTD (0001119774) (Filer)

    7/21/25 7:00:22 AM ET
    $CGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGEN
    Leadership Updates

    Live Leadership Updates

    View All

    Cognyte Elects Two New Board Members to Strengthen Expertise and Drive Growth

    Announcement reflects company's commitment to augment Board of Directors with industry-experienced executives from both the government and software sectors Cognyte Software Ltd. (NASDAQ:CGNT) ("Cognyte"), a global leader in investigative analytics software, today announced the appointment of two new members to its Board of Directors. Matthew O'Neill and Nurit Benjamini will join the board on March 1, 2025, and March 31, 2025, respectively, reflecting the company's commitment to add independent directors from the government and software sectors. Richard Nottenburg will be stepping down from his board position effective March 31, 2025. Having served with the United States Secret Service f

    2/18/25 8:00:00 AM ET
    $ALLT
    $BLRX
    $CGEN
    Computer Communications Equipment
    Telecommunications
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Compugen Appoints David Silberman as Chief Financial Officer

    HOLON, Israel, May 15, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the appointment of David Silberman as its new Chief Financial Officer effective August 15, 2024, taking over from Alberto Sessa who will depart Compugen on the same day. David will join Compugen from Oramed Pharmaceuticals Inc., where he served as Chief Financial Officer. "I am excited to welcome David to Compugen and believe his experience and insights will make him a pivotal additio

    5/15/24 7:00:00 AM ET
    $CGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer

    HOLON, Israel, Feb. 15, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the appointment of Michelle Mahler, M.D., as Chief Medical Officer, effective March 1, 2024. Michelle will succeed Henry Adewoye, M.D., who is leaving Compugen to pursue other opportunities effective February 29, 2024, after 6 years with Compugen. "I am delighted that Michelle will join the management team as Chief Medical Officer at a very exciting time for Compugen," said Anat Coh

    2/15/24 7:00:00 AM ET
    $CGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Compugen Ltd. (Amendment)

    SC 13G/A - COMPUGEN LTD (0001119774) (Subject)

    2/10/23 10:30:03 AM ET
    $CGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Compugen Ltd. (Amendment)

    SC 13G/A - COMPUGEN LTD (0001119774) (Subject)

    2/3/23 6:10:06 AM ET
    $CGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Compugen Ltd. (Amendment)

    SC 13G/A - COMPUGEN LTD (0001119774) (Subject)

    2/9/22 2:26:16 PM ET
    $CGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGEN
    Financials

    Live finance-specific insights

    View All

    Compugen Reports Second Quarter 2025 Results

    First patient dosed in MAIA-ovarian platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer in July 2025Pooled analysis from three previously reported Phase 1 trials of COM701 in platinum resistant ovarian cancer to be presented at ESMO 2025Recruitment ongoing in Phase 1 trial of GS-0321 (COM503) a potential first-in-class anti-IL18BP antibody licensed to GileadPartner AstraZeneca plans to share updated rilvegostomig data from Phase 2 ARTEMIDE-01 in NSCLC and first data from Phase 2 TROPION-PanTumor03 in bladder cancer at ESMO 2025Solid financial position with cash runway expected to fund operations into 2027HOLON, Israel, Aug. 6, 2025 /PRNewswire/ -- 

    8/6/25 7:00:00 AM ET
    $CGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Compugen to Release Second Quarter 2025 Results on Wednesday, August 6, 2025

    HOLON, Israel, July 23, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery powered by AI/ML, today announced that the Company will release its second quarter 2025 financial results on Wednesday, August 6, 2025, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET. To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, which i

    7/23/25 7:00:00 AM ET
    $CGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Compugen Reports First Quarter 2025 Results

    Initiated platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer in Q2 2025Recruitment ongoing in the first in human Phase 1 trial of GS-0321 (previously COM503), a potential first-in-class anti-IL18BP antibody licensed to GileadPartner AstraZeneca expanded their rilvegostomig program to ten Phase 3 trials across lung, gastrointestinal and endometrial cancers and plans to share early data for rilvegostomig at ASCOSolid financial position with cash runway expected to fund operations into 2027Key leadership transitions to take effect in September 2025HOLON, Israel, May 19, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage ca

    5/19/25 7:00:00 AM ET
    $CGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care